Skip to main content

Advertisement

SpringerLink
Log in

The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review

  • Review
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Aims and rationale

The purpose of this study was to review whether methylenedioxymethamphetamine (MDMA) has the appropriate pharmacodynamic profile to be a therapeutic agent.

Materials and methods

Empirical descriptions of MDMA’s subjective effects in humans will be reviewed to evaluate the proposal that MDMA has psychotherapeutic properties. The focus will be published evidence on its functional effects in therapeutic, medical, and other situations.

Results

MDMA is a powerful central nervous system (CNS) stimulant which affects several neurotransmitter systems and intensifies a range of psychobiological functions. Its acute mood effects can be very positive and life enhancing, and the affirmative cognitions engendered during MDMA therapy may well endure afterwards. However, MDMA also has a number of potential anti-therapeutic characteristics. Acutely, it can also intensify negative cognitions, and these may similarly endure over time. Psychotherapists have found that setting, intention, and expectancy are crucial for a positive outcome, but these factors cannot be guaranteed. Post-MDMA, there is a period of neurotransmitter recovery when low moods predominate, and these may exacerbate psychiatric distress. The explanations proposed for MDMA-assisted therapy are all psychodynamic, and a neurochemical model needs to be outlined. It has been suggested that enduring therapeutic gains can follow a single session, but again, this lacks a clear psychopharmacological rationale. Finally, diathesis–stress models suggest that psychiatric individuals are more prone to acute and chronic abreactions to CNS stimulants such as MDMA.

Conclusions

There are a number of issues which need to be addressed before it can be argued that MDMA might be clinically useful for psychotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Adamson S, Metzner R (1988) The nature of the MDMA experience and its role in healing, psychotherapy, and spiritual practice. ReVision. J Conscious Change 10:52–79

    Google Scholar 

  • Baylen CA, Rosenberg H (2006) A review of the acute subjective effects of MDMA/ecstasy. Addiction 101:933–947

    Article  PubMed  Google Scholar 

  • Bouso JC (2001) Using MDMA in the treatment of post-traumatic stress disorder. In: Holland J (ed) Ecstasy: the complete guide. Park Street Press, Rochester

    Google Scholar 

  • Buchert R, Thomasius R, Petersen K, Wilke F, Obrocki J, Nebeling B, Wartberg L, Zapletalova P, Clausen M (2006) Reversibility of ecstasy-induced reduction in serotonin transporter availability in polydrug ecstasy users. Eur J Nucl Med Mol Imaging 33:188–199

    Article  PubMed  CAS  Google Scholar 

  • Butler GKL, Montgomery AMJ (2004) Impulsivity, risk taking and recreational ‘ecstasy’ (MDMA) use. Drug Alcohol Depend 76:55–62

    Article  PubMed  CAS  Google Scholar 

  • Caton CL, Samet S, Hasin DS (2000) When acute-stage psychosis and substance use co-occur: differentiating substance-induced and primary psychotic disorders. J Psychiatr Pract 6:256–266

    Article  PubMed  CAS  Google Scholar 

  • Chack E (2004) The ups and downs of ecstasy. Nature 429:126–128

    Article  CAS  Google Scholar 

  • Cohen RS (1998) The love drug: marching to the beat of ecstasy. Haworth Medical Press, New York State

    Google Scholar 

  • Cole JC, Bailey M, Sumnall HR, Wagstaff GF, King LA (2002) The contents of ecstasy tablets: implications for the study of their long-term effects. Addiction 97:1531–1536

    Article  PubMed  Google Scholar 

  • Curran HV, Travill RA (1997) Mood and cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”): weekend “high” followed by mid-week “low”. Addiction 92:821–831

    Article  PubMed  CAS  Google Scholar 

  • Curran HV, Rees H, Hoare T, Hoshi R, Bond A (2004) Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users. Psychopharmacology 173:425–433

    Article  PubMed  CAS  Google Scholar 

  • Darvesh AS, Gudelsky GA (2005) Evidence for a role of energy dysregulation in the MDMA-induced depletion of brain 5-HT. Brain Res 21:168–175

    Article  CAS  Google Scholar 

  • Davidson JR (2004) Remission in post-traumatic stress disorder (PTSD): effects of sertraline as assessed by the Davidson Trauma Scale, Clinical Global Impressions and the Clinician-Administered PTSD scale. Int Clin Psychopharmacol 19:85–87

    Article  PubMed  Google Scholar 

  • Davison D, Parrott AC (1997) Ecstasy in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol 12:91–97

    Google Scholar 

  • De la Torre R, Farre M (2004) Neurotoxicity of MDMA (ecstasy): the limitations of scaling from animals to humans. Trends Pharmacol Sci 25:505–508

    Article  PubMed  CAS  Google Scholar 

  • Dittrich A (1994) Psychological aspects of altered states of consciousness of the LSD type. In: Pletscher A, Ladewig D (eds) Fifty years of LSD: current status and future perspectives of hallucinogens. Parthenon, New York

    Google Scholar 

  • Doblin R (2002) A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA. J Psychoact Drugs 34:185–194

    Google Scholar 

  • Downing J (1986) The psychological and physiological effects of MDMA in normal volunteers. J Psychoact Drugs 18:335–339

    CAS  Google Scholar 

  • Dumont GJ, Verkes RJ (2006) A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J Psychopharmacol 20:176–187

    Article  PubMed  CAS  Google Scholar 

  • Gahlinger PM (2004) Club drugs: MDMA, gamma-hydroxybutyrate (GHB), Rohypnol, and ketamine. Am Fam Phys 69:2619–2626

    Google Scholar 

  • Gamma A, Buck A, Berthold T, Liechti ME, Vollenweider FX (2000) 3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H2 15 O]-PET in healthy humans. Neuropsychopharmacology 23:388–395

    Article  PubMed  CAS  Google Scholar 

  • Gerra G, Zaimovic A, Ampollini R, Giusti F, Delsignore R, Raggi MA, Laviola G, Macchia T, Brambilla F (2001) Experimentally induced aggressive behavior in subjects with 3,4-methylenedioxy-methamphetamine (“Ecstasy”) use history: psychobiological correlates. J Subst Abuse 13:471–491

    Article  PubMed  CAS  Google Scholar 

  • Green AR, Mechan AO, Elliott JM, O’Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) Pharmacol Rev 55:463–508

    Article  PubMed  CAS  Google Scholar 

  • Greer G (1985) Using MDMA in psychotherapy. Adv J Inst Adv Health 2:57–59

    Google Scholar 

  • Greer G, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoact Drugs 18:319–327

    CAS  Google Scholar 

  • Greer G, Tolbert R (1990) The therapeutic use of MDMA. In: Peroutka SJ (ed) The clinical, pharmacological and neurotoxicological effects of the drug MDMA. Kluwer, New York

    Google Scholar 

  • Greer G, Tolbert R (1998) A method for conducting therapeutic sessions with MDMA. J Psychoact Drugs 30:371–379

    CAS  Google Scholar 

  • Grinspoon L, Bakalar JB (1986) Can drugs be used to enhance the psychotherapeutic process? Am J Psychother 40:393–404

    PubMed  CAS  Google Scholar 

  • Grob CS, Poland RE, Chang L, Ernst T (1996) Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav Brain Res 73:103–107

    Article  PubMed  CAS  Google Scholar 

  • Guillot C (2005) A clinical crossroads for MDMA. J Psychoact Drugs 37:445–447

    Google Scholar 

  • Halpern JH (2003) Hallucinogens: an update. Curr Psychiatry Rep 5:347–354

    PubMed  Google Scholar 

  • Hegadoren KM, Baker GB, Bourin M (1998) 3,4-Methylenedioxy analogues of amphetamine: defining the risks to humans. Neurosci Biobehav Rev 23:539–553

    Article  Google Scholar 

  • Holland J (2001a) Ecstasy: the complete guide. Park Street Press, Rochester

    Google Scholar 

  • Holland J (2001b) Using MDMA in the treatment of schizophrenia. In: Holland J (ed) Ecstasy: the complete guide. Park Street Press, Rochester

    Google Scholar 

  • Holland J, Greer G (2001) Clinical experience with MDMA assisted psychotherapy. In: Holland J (ed) Ecstasy: the complete guide. Park Street Press, Rochester

    Google Scholar 

  • Huether G, Zhou D, Ryuther E (1997) Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) and its congeners. J Neural Transmiss 104:771–794

    Article  CAS  Google Scholar 

  • Huizink AC, Ferdinand RF, van der Ende J, Verhulst FC (2006) Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study. Brit Med J 332:825–828

    Article  PubMed  Google Scholar 

  • Iversen L (2006) Speed, ecstasy, ritalin: the science of the amphetamines. Oxford University Press, Oxford

    Google Scholar 

  • Julien RM (2001) A primer of drug action. Freeman, New York

    Google Scholar 

  • Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, Cooper TB, Macdougall L, Abi-Saab W, D’Souza DC (2005) Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62:985–994

    Article  PubMed  CAS  Google Scholar 

  • Kurland AA, Grof S, Pahnke WN, Goodman LE (1973) Psychedelic drug assisted psychotherapy in patients with terminal cancer. In: Goldberg IK, Malite S, Kutscher AH (eds) Psychopharmacological agents for the terminally ill and bereaved. Columbia University Press, New York

    Google Scholar 

  • Leary T (1969) The effects of consciousness-expanding drugs on prisoner rehabilitation. Psychedelic Rev 10:29–44

    Google Scholar 

  • Liechti ME, Vollenweider FX (2000) The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers. J Psychopharmacol 14:269–274

    Article  PubMed  CAS  Google Scholar 

  • Liechti ME, Gamma A, Vollenweider FX (2001) Gender differences in the subjective effects of MDMA. Psychopharmacology 154:161–168

    Article  PubMed  CAS  Google Scholar 

  • Liester MB, Grob CS, Bravo GL, Walsh RN (1992) Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J of Nerv Ment Dis 180:345–352

    Article  CAS  Google Scholar 

  • Lock J, Kissling C, Thome J, Parrott AC (2006) Hormonal, temperature and mood changes in recreational Ecstasy/MDMA users out clubbing: a brief prospective study. J Psychopharmacol 20:a52

    Google Scholar 

  • MacInnes N, Handley SL, Harding GFA (2001) Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol 15:181–186

    PubMed  CAS  Google Scholar 

  • McCann UD, Eligulashvili V, Ricaurte GA (2000) 3,4 methylenedioxymethamphetamine (“Ecstasy”)-induced serotonin neurotoxicity: clinical studies. Neuropsychobiology 42:11–16

    Article  PubMed  CAS  Google Scholar 

  • Metzner R (1998) Hallucinogenic drugs and plants in psychotherapy and shamanism. J Psychoact Drugs 30:333–341

    CAS  Google Scholar 

  • Metzner R, Adamson S (2001) Using MDMA in healing, psychotherapy and spiritual practice. In: Holland J (ed) Ecstasy: the complete guide. Park Street Press, Rochester, USA

    Google Scholar 

  • Mithoefer MC (2005) Phase 2 clinical trial testing the safety and efficacy of MDMA-assisted psychotherapy in subjects with chronic post traumatic stress disorder. Study #63-384 protocol downloaded from MAPS website

  • Naranjo C (2001) Experience with interpersonal psychedelics. In: Holland J (ed) Ecstasy: the complete guide. Park Street Press, Rochester

    Google Scholar 

  • Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoact Drugs 18:305–313

    CAS  Google Scholar 

  • Nutt DJ (2006) A tale of two E’s. J Psychopharmacol 20:315–317

    Article  PubMed  Google Scholar 

  • O’Regan MC, Clow A (2004) Decreased pain tolerance and mood in recreational users of MDMA. Psychopharmacology 173:446–451

    Article  PubMed  CAS  Google Scholar 

  • Parrott AC (2001) Human psychopharmacology of Ecstasy (MDMA): a review of fifteen years of empirical research. Hum Psychopharmacol 16:557–577

    Article  PubMed  CAS  Google Scholar 

  • Parrott AC (2002) Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav 71:837–844

    Article  PubMed  CAS  Google Scholar 

  • Parrott AC (2004a) Is Ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, dosage levels, and the changing perceptions of purity. Psychopharmacology 173:234–241

    Article  PubMed  CAS  Google Scholar 

  • Parrott AC (2004b) MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 50:329–335

    Article  PubMed  CAS  Google Scholar 

  • Parrott AC (2006) MDMA in humans: factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bio-energetic stress. J Psychopharmacol 20:147–163

    Article  PubMed  CAS  Google Scholar 

  • Parrott AC (2007a) Ecstasy versus alcohol: Tolstoy and the variations of unhappiness. J Psychopharmacol 21:3–6

    Article  PubMed  CAS  Google Scholar 

  • Parrott AC (2007b) Alcohol, ecstasy, Aldous Huxley’s ‘soma’. J Psychopharmacol 21:8–9

    Article  PubMed  CAS  Google Scholar 

  • Parrott AC, Lasky J (1998) Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance. Psychopharmacology 139:261–268

    Article  PubMed  CAS  Google Scholar 

  • Parrott AC, Sisk E, Turner J (2000) Psychobiological problems in heavy ‘ecstasy’ (MDMA) polydrug users. Drug Alcohol Depend 60:105–110

    Article  PubMed  CAS  Google Scholar 

  • Parrott AC, Milani R, Parmar R, Turner JJD (2001) Ecstasy polydrug users and other recreational drug users in Britain and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 159:77–82

    Article  PubMed  CAS  Google Scholar 

  • Parrott AC, Buchanan T, Scholey AB, Heffernan TM, Ling J, Rodgers J (2002) Ecstasy attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 17:309–312

    Article  PubMed  CAS  Google Scholar 

  • Parrott A, Morinan A, Moss M, Scholey A (2004) Understanding drugs and behaviour. Wiley, Chichester

    Google Scholar 

  • Quinton MS, Yamamoto BK (2006) Causes and consequences of methamphetamine and MDMA toxicity. AAPS J 8:337–347

    Article  Google Scholar 

  • Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ (2006) Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol 20:164–175

    Article  PubMed  CAS  Google Scholar 

  • Ricaurte GA, Yuan J, McCann UD (2000) (±) 3,4-methylenedioxymethamphetamine (MDMA, “Ecstasy”)-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42:5–10

    Article  PubMed  CAS  Google Scholar 

  • Riedlinger JE, Montagne D (2001) Using MDMA in the treatment of depression. In: Holland J (ed) Ecstasy: the complete guide. Park Street Press, Rochester

    Google Scholar 

  • Riedlinger TJ, Riedlinger JE (1994) Psychedelic and entactogenic drugs in the treatment of depression. J Psychoact Drugs 26:41–55

    CAS  Google Scholar 

  • Rodgers J, Buchanan T, Pearson C, Parrott AC, Ling J, Heffernan TM, Scholey AB (2006) Differential experiences of the psychobiological sequelae of ecstasy use: quantitative and qualitative data from an internet study. J Psychopharmacol 20:437–446

    Article  PubMed  Google Scholar 

  • Saunders N (1997) Ecstasy reconsidered. Neal’s Yard Desktop Publishing, London

    Google Scholar 

  • Schifano F (2000) Potential human neurotoxicity of MDMA (‘Ecstasy’): subjective self-reports, evidence form an Italian drug addiction centre and clinical case studies. Neuropsychobiology 42:25–33

    Article  PubMed  CAS  Google Scholar 

  • Scholey AB, Parrott AC, Buchanan T, Heffernan T, Ling J, Rodgers J (2004) Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a www study. Addict Behav 29:743–752

    Article  PubMed  Google Scholar 

  • Shulgin AT (1986) The background and chemistry of MDMA. J Psychoact Drugs 18:291–304

    CAS  Google Scholar 

  • Shulgin AT, Nichols DE (1978) Characterization of three new psychotomimetics. In: Stillman RC, Willette RE (eds) The psychopharmacology of the hallucinogens. Pergamon, New York

    Google Scholar 

  • Soar K, Turner JJD, Parrott AC (2001) Psychiatric disorders in recreational ecstasy (MDMA) users: a literature review focusing upon personal predisposition factors and drug histories. Hum Psychopharmacol 16:641–646

    Article  PubMed  Google Scholar 

  • Stone MH (1973) Drug-related schizophrenic syndromes. Int J Psychiatr 11:391–437

    CAS  Google Scholar 

  • Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A (2006) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 20:211–225

    Article  PubMed  CAS  Google Scholar 

  • Turner JJD, Nicolas L, Parrott AC (1998) Reduced calorie intake in the week following weekend MDMA (ecstasy) use. J Psychopharmacol 12:a43

    Google Scholar 

  • Tucker P, Potter-Kimball R, Wyatt DB, Parker DE, Burgin C, Jones DE, Masters BK (2003) Can physiologic assessment and side effects tease out differences in PTSD trials? A double-blind comparison of citalopram, sertraline, and placebo. Psychopharmacol Bull 37:135–149

    PubMed  Google Scholar 

  • Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (‘ecstasy’) in MDMA-naive healthy volunteers. Neuropsychopharmacology 19:241–251

    Article  PubMed  CAS  Google Scholar 

  • Wolff K, Tsapakis EM, Winstock AR, Hartley D, Holt D, Forsling ML, Aitchison KJ (2006) Vasopressin and oxytocin secretion in response to the consumption of ecstacy in a clubbing population. J Psychopharmacol 20:400–410

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychology, University of Wales Swansea, Swansea, SA2 8PP, Wales, UK

    A. C. Parrott

Authors
  1. A. C. Parrott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. C. Parrott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Parrott, A.C. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review. Psychopharmacology 191, 181–193 (2007). https://doi.org/10.1007/s00213-007-0703-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-007-0703-5

Keywords

Search

Navigation